IlluminOss Medical completes clinical trial enrollment with 80 patients: 5 key takeaways

Written by Anuja Vaidya | July 19, 2016 | Print  |

IlluminOss Medical has completed enrollment in its first U.S. clinical trial for its IlluminOss System.

Here are five key takeaways:

 

1. The trial includes 13 sites and 80 patients.

 

2. The IlluminOss System uses proprietary bone stabilization technology, allowing for fracture fixation through patient-specific intramedullary implants.

 

3. The system was developed as an alternative to standard-of-care nails and plates.

 

4. Approved in international markets, the system has been used to treat more than 1,500 patients worldwide.

 

5. The outcomes data from the trial allow the company to submit a DeNovo marketing application to the FDA.

 

More articles on devices:
NuVasive, Bioventus, DFINE & more: 17 key notes
Medtech sells 13 ROSA robots in Q4 2016 — 5 highlights
Dr. Nicole Ehrhart's preclinical study affirms AlloStem Cellular Bone Allograft effectiveness: 5 key takeaways

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months